Grifols (GRF) Q4 2024 earnings summary

Executive summary

• Achieved record revenues and adjusted EBITDA for both Q4 and full year 2024, with FY2024 revenue at EUR 7,212 million, up 10.3% year-over-year, and Q4 revenue at EUR 1,976 million, up 13.6%.

• Adjusted EBITDA reached EUR 1,779 million for FY2024 (24.7% margin), up 21.7% year-over-year; Q4 Adjusted EBITDA was EUR 526 million (26.6% margin), up 18.6%.

• Free cash flow for FY2024 reached EUR 266 million, with Q4 FCF at EUR 335 million, exceeding initial guidance.

• Strengthened financial position and liquidity through asset sales, deleveraging, and improved working capital management; leverage ratio reduced to 4.6x by year-end.

• Advanced innovation pipeline, achieving all 2024 milestones, including regulatory progress for fibrinogen and new research initiatives.

Financial highlights

• Gross profit for FY2024 was EUR 2,795 million (38.7% margin), up 12.5% year-over-year; Q4 gross profit was EUR 766 million (38.8% margin), up 10.8%.

• Net income for FY2024 was EUR 157 million, up 271% year-over-year; Q4 net income was EUR 69 million, up 22%.

• Operating income (EBIT) for FY2024 was EUR 1,192 million (16.5% margin), up 52.4% year-over-year.

• Free cash flow pre-M&A conversion rate reached 15% in FY2024.

• Cash and cash equivalents at year-end were EUR 980 million, with total liquidity of EUR 1.9 billion.

Outlook and guidance

• Management expects continued improvements in financial and operational performance in 2025, with a focus on sustainable growth, margin expansion, and further deleveraging.

• No significant CapEx required for donor or manufacturing expansion in the next 3-4 years; focus on optimizing existing capacity.

• 2025 guidance and midterm strategic plan to be detailed at Capital Markets Day.